Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-017-1176-0
Abstract: BackgroundRadium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic… read more here.
Keywords: japanese patients; 223 dichloride; radium 223; prostate cancer ... See more keywords
Radium-223 Dichloride in Peritoneal Dialysate Following Treatment of Metastatic Castration-resistant Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Health physics"
DOI: 10.1097/hp.0000000000001518
Abstract: ABSTRACT Radium-223 dichloride was administrated to a patient with castration-resistant metastatic prostate cancer (mCRPC) undergoing in-home peritoneal dialysis. The peritoneal dialysate and tubing sets were collected following four treatment cycles and analyzed for removable contamination,… read more here.
Keywords: prostate cancer; peritoneal dialysate; castration resistant; radium 223 ... See more keywords
Effectiveness and safety of radium‐223 dichloride in patients with castration‐resistant prostate cancer and bone metastases in real‐world practice: A multi‐institutional study
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Urology"
DOI: 10.1111/iju.15078
Abstract: Radium‐223 (Ra‐223) dichloride is the bone‐targeted radioligand therapy that prolongs overall survival (OS) in patients with bone‐metastatic castration‐resistant prostate cancer (CRPC). We aimed to evaluate the safety and effectiveness of this treatment in real‐world practice. read more here.
Keywords: prostate cancer; resistant prostate; castration resistant; radium 223 ... See more keywords
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Sign Up to like & getrecommendations! Published in 2020 at "BMC Cancer"
DOI: 10.1186/s12885-020-07000-2
Abstract: Background Metastasis directed therapy (MDT) for patients with oligometastatic disease is associated with improvements in progression free survival (PFS) and overall survival (OS) compared to systemic therapy alone. Additionally, within a prostate-cancer-specific cohort, MDT is… read more here.
Keywords: trial; 223 dichloride; progression; radium 223 ... See more keywords
Radium 223 dichloride for prostate cancer treatment
Sign Up to like & getrecommendations! Published in 2017 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s122417
Abstract: Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo®) is a radioactive isotope that induces irreversible DNA double-strand… read more here.
Keywords: 223 dichloride; radium 223; prostate cancer;